Tofacitinib for Treatment of Moderate COVID-19

Summary

The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-99 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation.

Timeline

Start

2020-10-14

Primary completion

2021-02-28

Completion

2021-02-28

Outcome

Outcome not reported

Stopped (Enrollment): “Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.”

Drugs

Indications